BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pirfenidone (Esbriet) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Pirfenidone (Esbriet)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06928272-6205@assetmemo.bio
DTSTAMP:20261121T004954Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pirfenidone (Esbriet): Phase 3 readout est. (NCT06928272)
DESCRIPTION:Pirfenidone (Esbriet)\, phase 3.\nStudy: Long Covid (LC)-REVITA
 LIZE - A Long Covid Repurposed Drug Study\nEstimated primary completion: D
 ecember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pirfeni
 done-esbriet#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06928272
URL:https://assetmemo.bio/drug/pirfenidone-esbriet#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07268677-6205@assetmemo.bio
DTSTAMP:20261121T004954Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Pirfenidone (Esbriet): Phase 2 readout est. (NCT07268677)
DESCRIPTION:Pirfenidone (Esbriet)\, phase 2.\nStudy: A Single-arm Clinical 
 Study Evaluating Pirfenidone and Sintilimab in Combination With Standard N
 eoadjuvant Chemotherapy for Colorectal Cancer Patients With Peritoneal Met
 astasis.\nEstimated primary completion: 1 December 2026. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/pirfenidone-esbriet#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07268677
URL:https://assetmemo.bio/drug/pirfenidone-esbriet#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07388680-6205@assetmemo.bio
DTSTAMP:20261121T004954Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Pirfenidone (Esbriet): Phase 2/3 readout est. (NCT07388680)
DESCRIPTION:Pirfenidone (Esbriet)\, phase 2/3.\nStudy: Pirfenidone Capsules
  in the Treatment of Radiation-induced Lung Injury With or Without Immune 
 Pneumonia\nEstimated primary completion: 30 December 2026. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/pirfenidone-esbriet#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07388680
URL:https://assetmemo.bio/drug/pirfenidone-esbriet#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07161791-6205@assetmemo.bio
DTSTAMP:20261121T004954Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pirfenidone (Esbriet): Phase 1/2 readout est. (NCT07161791)
DESCRIPTION:Pirfenidone (Esbriet)\, phase 1/2.\nStudy: Camrelizumab\, Pirfe
 nidone\, and Chemotherapy in the Treatment of Advanced Triple-Negative Bre
 ast Cancer\nEstimated primary completion: 31 December 2026. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/pirfenidone-esbriet#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07161791
URL:https://assetmemo.bio/drug/pirfenidone-esbriet#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04467723-6205@assetmemo.bio
DTSTAMP:20261121T004954Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Pirfenidone (Esbriet): Phase 1/2 readout est. (NCT04467723)
DESCRIPTION:Pirfenidone (Esbriet)\, phase 1/2.\nStudy: Combination of Atezo
 lizumab and Pirfenidone in Second-line and Beyond NSCLC\nEstimated primary
  completion: 1 January 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/pirfenidone-esbriet#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT04467723
URL:https://assetmemo.bio/drug/pirfenidone-esbriet#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03109288-6205@assetmemo.bio
DTSTAMP:20261121T004954Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Pirfenidone (Esbriet): Phase 1/2 readout est. (NCT03109288)
DESCRIPTION:Pirfenidone (Esbriet)\, phase 1/2.\nStudy: Targeting Residual A
 ctivity By Precision\, Biomarker-Guided Combination Therapies of Multiple 
 Sclerosis (TRAP-MS)\nEstimated primary completion: 1 January 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/pirfenidone-esbriet#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT03109288
URL:https://assetmemo.bio/drug/pirfenidone-esbriet#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07644286-6205@assetmemo.bio
DTSTAMP:20261121T004954Z
DTSTART;VALUE=DATE:20270125
DTEND;VALUE=DATE:20270126
SUMMARY:Pirfenidone (Esbriet): Phase 2 readout est. (NCT07644286)
DESCRIPTION:Pirfenidone (Esbriet)\, phase 2.\nStudy: A Phase II Study of Pi
 rfenidone Plus PD-1 Inhibitor With or Without Hypofractionated Radiotherap
 y for Refractory pMMR/MSS Colorectal Cancer\nEstimated primary completion:
  25 January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pir
 fenidone-esbriet#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07644286
URL:https://assetmemo.bio/drug/pirfenidone-esbriet#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05704166-6205@assetmemo.bio
DTSTAMP:20261121T004954Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Pirfenidone (Esbriet): Phase 2 readout est. (NCT05704166)
DESCRIPTION:Pirfenidone (Esbriet)\, phase 2.\nStudy: PirfenidoneVsPlacebo a
 s Prophylaxis Against Acute Radiation-induced Lung Injury Following HFRT i
 n Breast Cancer Patients\nEstimated primary completion: 31 July 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/pirfenidone-esbriet#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05704166
URL:https://assetmemo.bio/drug/pirfenidone-esbriet#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07141810-6205@assetmemo.bio
DTSTAMP:20261121T004954Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Pirfenidone (Esbriet): Phase 4 readout est. (NCT07141810)
DESCRIPTION:Pirfenidone (Esbriet)\, phase 4.\nStudy: Efficacy and Safety of
  Early Antifibrotic Therapy for Non-progressive Fibrotic Interstitial Lung
  Disease\nEstimated primary completion: 30 April 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/pirfenidone-esbriet#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07141810
URL:https://assetmemo.bio/drug/pirfenidone-esbriet#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06253117-6205@assetmemo.bio
DTSTAMP:20261121T004954Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Pirfenidone (Esbriet): Phase 2 readout est. (NCT06253117)
DESCRIPTION:Pirfenidone (Esbriet)\, phase 2.\nStudy: Evaluation of Pirfenid
 one as a Novel Therapeutic Strategy Against Recurrent Acute Pancreatitis.\
 nEstimated primary completion: 1 September 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/pirfenidone-esbriet#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06253117
URL:https://assetmemo.bio/drug/pirfenidone-esbriet#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07325357-6205@assetmemo.bio
DTSTAMP:20261121T004954Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Pirfenidone (Esbriet): Phase 4 readout est. (NCT07325357)
DESCRIPTION:Pirfenidone (Esbriet)\, phase 4.\nStudy: Effect of Pirfenidone 
 on TA Fibrosis\nEstimated primary completion: 31 December 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/pirfenidone-esbriet#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07325357
URL:https://assetmemo.bio/drug/pirfenidone-esbriet#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07654517-6205@assetmemo.bio
DTSTAMP:20261121T004954Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Pirfenidone (Esbriet): Phase 1 readout est. (NCT07654517)
DESCRIPTION:Pirfenidone (Esbriet)\, phase 1.\nStudy: Pirfenidone for Idiopa
 thic Subglottic Stenosis: A Pilot Trial of Tolerability and Feasibility\nE
 stimated primary completion: 31 March 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/pirfenidone-esbriet#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07654517
URL:https://assetmemo.bio/drug/pirfenidone-esbriet#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07755813-6205@assetmemo.bio
DTSTAMP:20261121T004954Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Pirfenidone (Esbriet): Phase 2 readout est. (NCT07755813)
DESCRIPTION:Pirfenidone (Esbriet)\, phase 2.\nStudy: Pirfenidone as Treatme
 nt of Chronic Pancreatitis\nEstimated primary completion: August 2030. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/pirfenidone-esbriet#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07755813
URL:https://assetmemo.bio/drug/pirfenidone-esbriet#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07856914-6205@assetmemo.bio
DTSTAMP:20261121T004954Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Pirfenidone (Esbriet): Phase 2 readout est. (NCT07856914)
DESCRIPTION:Pirfenidone (Esbriet)\, phase 2.\nStudy: Paricalcitol Versus Pi
 rfenidone for Improving Surgical Resectability in Patients With Peritoneal
  Cancer\nEstimated primary completion: September 2030. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/pirfenidone-esbriet#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07856914
URL:https://assetmemo.bio/drug/pirfenidone-esbriet#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
